Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?

To my knowledge, there is no definitive answer to this question, and I think the vast majority of providers do not alter their recommendations for duration. A brief discussion of the issue and some evidence is offered below, for anyone interested.

A recent review in the Red Journal (Roy et al., PMID...